Latest Financial Updates News

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.

Bapcor Limited will announce its half-year financial results for the period ending December 2024 on 26 February, with a live briefing hosted by its top executives.

Sandfire Resources Limited has announced the release date for its December 2024 half-year financial results, scheduled for February 20, 2025, accompanied by a live teleconference and webcast for investors.

Viridis Mining and Minerals Limited has been reinstated to ASX quotation following a capital raising announcement, ending its trading suspension and signaling renewed investor confidence.

Medlab Clinical reports a near-empty cash balance and zero receipts in Q2 2025, while actively pursuing a business acquisition ahead of its ASX removal date.

DGR Global Limited's December 2024 quarterly report reveals active exploration progress, ongoing legal disputes over Armour Energy, and strategic financing initiatives aimed at sustaining growth.

St George Mining Limited progresses its strategic acquisition of the Araxá Niobium-REE Project while reporting promising exploration results across multiple Australian projects, underpinning its critical metals ambitions.

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Arrow Minerals reports a breakthrough at its Niagara Bauxite Project with high-grade mineralisation over 14km² and advances metallurgical testwork at Simandou North, backed by a $7 million funding round.

Intelligent Monitoring Group Limited has reaffirmed its FY25 adjusted EBITDA guidance above $38 million, reporting a robust $7.9 million operating cash flow for the first half of 2025. The company is advancing its strategic acquisitions and launching innovative video guarding services poised to disrupt the security sector.

IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.